Skip to main content
. 2016 Jan 4;11(3):413–422. doi: 10.2215/CJN.07900715

Table 1.

Baseline demographic and biochemical parameters

Parameter All Patients, n=1058 CKD Stage 3, n=435 CKD Stages 4 and 5, n=377 CKD Stage 5 Dialysis, n=246 P Value
Age, yr 58±13 61±11 58±12 53±14 <0.001
Men, % (N) 62.8 (665) 70.8 58.9 54.9 <0.001
BMI, kg/m2 28 (25–32) 29 (26–32) 28 (25–32) 27 (23–32) <0.001
SBP, mmHg 140 (129–156) 142 (130–156) 143 (130–159) 137 (123–153) <0.001
DBP, mmHg 81 (75–89) 81 (75–89) 81 (74–88) 80 (70–90) 0.10
Cholesterol, mg/dl 178±40 187±37 177±38 163±42 <0.001
LDL-cholesterol, mg/dl 101±34 110±32 100±34 87±32 <0.001
HDL-cholesterol, mg/dl 46 (38–57) 47 (39–56) 47 (37–59) 44 (36–54) 0.01
Triglycerides, mg/dl 126 (92–177) 125 (96–175) 127 (92–185) 124 (82–176) 0.81
Glucose, mg/dl 99 (88–118) 103 (92–125) 98 (89–112) 91 (82–113) <0.001
hs-CRP, mg/L 1.88 (0.92–4.7) 1.83 (0.92–4.07) 1.68 (0.82–4.22) 2.44 (1.14–7.16) 0.002
eGFR, ml/min per 1.73 m2 26 (12–40) 43 (36–50) 21 (15–25) 6.6 (5.2–9.1) <0.001
ABI 1.04 (0.95–1.15) 1.00 (0.93–1.12) 1.04 (0.95–1.15) 1.07 (0.96–1.25) <0.001
c-IMT, mm 0.71 (0.62–0.82) 0.75 (0.66–0.84) 0.68 (0.59–0.81) 0.69 (0.60–0.79) <0.001
Smoker, % (N) 57.2 (605) 60.9 (265) 55.7 (210) 52.8 (130) 0.09
Dyslipemia, % (N) 64.6 (684) 71.7 (312) 69.0 (260) 45.5 (112) <0.001
 Medical treatment, % (N) 57.0 (603) 57.7 (251) 67.1 (253) 40.2 (99)
Diabetes mellitus, % (N) 29.0 (307) 32.2 (140) 30.0 (113) 22.0 (54) 0.02
 Medical treatment, % (N) 27.9 (295) 31.9 (139) 28.6 (108) 19.5 (48)
Hypertension, % (N) 92.1 (974) 91.5 (398) 96.0 (362) 87.0 (214) <0.001
 Medical treatment, % (N) 89.2 (944) 92.6 (403) 95.8 (361) 73.2 (180)
Familial CVD, % (N) 8.5 (90) 9.4 (41) 9.0 (34) 6.1 (15) 0.30
sTWEAK, pg/ml 389 (254–576) 459 (323–631) 405 (286–549) 214 (115–346) <0.001

Results are expressed as means±SDs or medians (interquartile ranges). BMI, body mass index; SBP, systolic BP; DBP, diastolic BP; hs-CRP, high–sensitivity C-reactive protein; ABI, ankle-brachial index; c-IMT, carotid intima-media thickness; CVD, cardiovascular disease; sTWEAK, soluble TNF–like weak inducer of apoptosis.